China Pioneer Pharma Holdings Ltd
HKEX:1345
Income Statement
Earnings Waterfall
China Pioneer Pharma Holdings Ltd
Revenue
|
1.6B
CNY
|
Cost of Revenue
|
-898.4m
CNY
|
Gross Profit
|
668.2m
CNY
|
Operating Expenses
|
-486.7m
CNY
|
Operating Income
|
181.5m
CNY
|
Other Expenses
|
-35.8m
CNY
|
Net Income
|
145.7m
CNY
|
Income Statement
China Pioneer Pharma Holdings Ltd
Dec-2013 | Jun-2014 | Dec-2014 | Jun-2015 | Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||
Revenue |
1 272
N/A
|
1 460
+15%
|
1 540
+6%
|
1 605
+4%
|
1 461
-9%
|
1 464
+0%
|
1 790
+22%
|
2 012
+12%
|
2 154
+7%
|
2 077
-4%
|
1 624
-22%
|
1 293
-20%
|
1 316
+2%
|
1 318
+0%
|
1 332
+1%
|
1 395
+5%
|
1 435
+3%
|
1 408
-2%
|
1 556
+10%
|
1 634
+5%
|
1 567
-4%
|
|
Gross Profit | ||||||||||||||||||||||
Cost of Revenue |
(886)
|
(995)
|
(1 048)
|
(1 101)
|
(998)
|
(1 003)
|
(1 197)
|
(1 343)
|
(1 433)
|
(1 351)
|
(992)
|
(687)
|
(636)
|
(692)
|
(724)
|
(661)
|
(663)
|
(658)
|
(776)
|
(893)
|
(898)
|
|
Gross Profit |
387
N/A
|
465
+20%
|
492
+6%
|
503
+2%
|
463
-8%
|
461
0%
|
593
+29%
|
669
+13%
|
721
+8%
|
726
+1%
|
632
-13%
|
606
-4%
|
680
+12%
|
626
-8%
|
608
-3%
|
735
+21%
|
772
+5%
|
750
-3%
|
780
+4%
|
741
-5%
|
668
-10%
|
|
Operating Income | ||||||||||||||||||||||
Operating Expenses |
(98)
|
(158)
|
(194)
|
(196)
|
(177)
|
(225)
|
(333)
|
(343)
|
(404)
|
(458)
|
(477)
|
(514)
|
(537)
|
(507)
|
(521)
|
(589)
|
(576)
|
(540)
|
(535)
|
(517)
|
(487)
|
|
Selling, General & Administrative |
(135)
|
(162)
|
(212)
|
(219)
|
(214)
|
(245)
|
(366)
|
(398)
|
(430)
|
(466)
|
(489)
|
(534)
|
(559)
|
(525)
|
(533)
|
(599)
|
(585)
|
(555)
|
(548)
|
(564)
|
(535)
|
|
Depreciation & Amortization |
(1)
|
(1)
|
0
|
(6)
|
0
|
(10)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Operating Expenses |
38
|
5
|
18
|
29
|
37
|
31
|
32
|
55
|
26
|
8
|
11
|
19
|
22
|
18
|
11
|
10
|
9
|
14
|
13
|
47
|
48
|
|
Operating Income |
289
N/A
|
307
+6%
|
298
-3%
|
308
+3%
|
285
-7%
|
237
-17%
|
260
+10%
|
326
+25%
|
317
-3%
|
269
-15%
|
155
-42%
|
92
-41%
|
142
+55%
|
119
-16%
|
87
-27%
|
146
+68%
|
196
+35%
|
210
+7%
|
245
+17%
|
223
-9%
|
182
-19%
|
|
Pre-Tax Income | ||||||||||||||||||||||
Interest Income Expense |
(4)
|
4
|
4
|
8
|
(30)
|
(41)
|
(20)
|
(34)
|
(9)
|
9
|
(8)
|
(14)
|
(2)
|
7
|
5
|
0
|
11
|
16
|
17
|
15
|
(1)
|
|
Non-Reccuring Items |
(13)
|
(5)
|
2
|
13
|
(48)
|
(54)
|
43
|
30
|
1
|
8
|
(40)
|
(0)
|
8
|
(21)
|
4
|
(13)
|
(6)
|
27
|
32
|
(3)
|
(0)
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
273
N/A
|
306
+12%
|
305
0%
|
329
+8%
|
207
-37%
|
141
-32%
|
282
+100%
|
323
+14%
|
309
-4%
|
286
-8%
|
107
-63%
|
77
-28%
|
148
+93%
|
105
-29%
|
95
-9%
|
133
+40%
|
201
+51%
|
253
+26%
|
294
+16%
|
235
-20%
|
180
-23%
|
|
Net Income | ||||||||||||||||||||||
Tax Provision |
(37)
|
(45)
|
(44)
|
(43)
|
(34)
|
(29)
|
(44)
|
(42)
|
(29)
|
(27)
|
(22)
|
(15)
|
(45)
|
(69)
|
(44)
|
(44)
|
(61)
|
(59)
|
(65)
|
(55)
|
(51)
|
|
Income from Continuing Operations |
236
|
261
|
261
|
286
|
173
|
112
|
239
|
281
|
281
|
259
|
85
|
62
|
104
|
36
|
51
|
89
|
141
|
194
|
230
|
181
|
129
|
|
Income to Minority Interest |
3
|
2
|
1
|
1
|
2
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(0)
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
5
|
9
|
17
|
|
Net Income (Common) |
238
N/A
|
263
+10%
|
262
0%
|
287
+10%
|
174
-39%
|
111
-36%
|
237
+114%
|
280
+18%
|
279
0%
|
258
-7%
|
85
-67%
|
63
-26%
|
105
+67%
|
37
-65%
|
52
+43%
|
91
+73%
|
143
+57%
|
196
+37%
|
235
+20%
|
190
-19%
|
146
-23%
|
|
EPS (Diluted) |
0.22
N/A
|
0.21
-5%
|
0.2
-5%
|
0.21
+5%
|
0.13
-38%
|
0.09
-31%
|
0.18
+100%
|
0.22
+22%
|
0.22
N/A
|
0.2
-9%
|
0.07
-65%
|
0.05
-29%
|
0.09
+80%
|
0.03
-67%
|
0.04
+33%
|
0.08
+100%
|
0.12
+50%
|
0.16
+33%
|
0.2
+25%
|
0.16
-20%
|
0.12
-25%
|